leading brands of glp-1 agonists in biopharma Receptor Agonist Market Size & Analysis, 2026-2033 The Landscape Of GLP-1 Receptor

In the short-term, demand may be somewhat curbed by governments and insurers being slow to reimburse, high out-of-pocket costs, supply shortages and side effect fears

Obesity and impaired metabolic health increase risk of COVID-19-Related mortality in young and middle-aged adults to the level observed in older people: The LEOSS registry

Colin, I

These second order effects will become more far reaching as insurance coverage becomes wider for these drugs - this will be the differentiator between the risk/reward being better on the first-order beneficiaries (LLY and NVO) and the second-order plays like short bariatric surgery/sleep apnea/gyms/fast food & CPG

The FDA has had to issue warnings against fake Ozempic and other knock-off GLP-1 receptor agonists bought by those desperate for some of the positive benefits

When tested in obese cynomolgus monkeys, treatment with AT-7687 in combination with liraglutide results in lower total energy intake and significant body weight loss compared to placebo but no differences when compared to liraglutide alone